Stephens Inc. AR Invests $184,000 in Soligenix, Inc. (NASDAQ:SNGX)

Stephens Inc. AR purchased a new stake in shares of Soligenix, Inc. (NASDAQ:SNGX) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 46,262 shares of the biopharmaceutical company’s stock, valued at approximately $184,000. Stephens Inc. AR owned approximately 4.69% of Soligenix at the end of the most recent reporting period.

Separately, OLD National Bancorp IN bought a new stake in shares of Soligenix during the 2nd quarter worth approximately $26,000. Institutional investors and hedge funds own 3.60% of the company’s stock.

Soligenix Stock Up 0.9 %

Shares of NASDAQ SNGX opened at $3.50 on Friday. The business has a fifty day simple moving average of $3.78 and a two-hundred day simple moving average of $4.44. Soligenix, Inc. has a twelve month low of $1.83 and a twelve month high of $32.00.

Soligenix (NASDAQ:SNGX) last announced its quarterly earnings results on Friday, August 9th. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.11) by $0.80. Soligenix had a negative return on equity of 256.12% and a negative net margin of 1,473.38%. As a group, sell-side analysts expect that Soligenix, Inc. will post -5.1 EPS for the current year.

Soligenix Profile

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.